276 related articles for article (PubMed ID: 36296377)
1. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
2. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
Zhu K; Zhou L; Zou M; Ning S; Liu S; Zhou Y; Du K; Zhang X; Xia X
J Pharm Sci; 2020 Jun; 109(6):2038-2047. PubMed ID: 32173319
[TBL] [Abstract][Full Text] [Related]
3. Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin.
Zou M; Xu Y; Lin P; Zhou L; Xia X
J Liposome Res; 2023 Sep; 33(3):283-299. PubMed ID: 36594207
[TBL] [Abstract][Full Text] [Related]
4. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
5. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intracellular accumulation and cytotoxicity of bortezomib against liver cancer cells using N-stearyl lactobionamide surface modified solid lipid nanoparticles.
Mostafaei F; Hemmati S; Valizadeh H; Mahmoudian M; Sarfraz M; Abdi M; Torabi S; Baradaran B; Vosough M; Zakeri-Milani P
Int J Pharm; 2024 Jan; 649():123635. PubMed ID: 38000649
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.
Han M; Ji X; Li J; Ge Z; Luo B; Zhou K; Wang Q; Sun X; Zhang W; Li J
Int J Nanomedicine; 2020; 15():3433-3445. PubMed ID: 32523342
[TBL] [Abstract][Full Text] [Related]
11. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine.
Yao H; Zhao J; Wang Z; Lv J; Du G; Jin Y; Zhang Y; Song S; Han G
Colloids Surf B Biointerfaces; 2020 Dec; 196():111285. PubMed ID: 32771818
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhetinic Acid-Modified Norcantharidin Nanoparticles for Active Targeted Therapy of Hepatocellular Carcinoma.
Zhang H; Jiang Y; Ni X; Chen L; Wu M; Liu J; Yang B; Shan X; Yang L; Fan J; Chen Y; Wu J; Fu S
J Biomed Nanotechnol; 2018 Jan; 14(1):114-126. PubMed ID: 29463369
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and in vitro evaluation of curcumin-loaded albumin nanoparticles surface-functionalized with glycyrrhetinic acid.
Li J; Chen T; Deng F; Wan J; Tang Y; Yuan P; Zhang L
Int J Nanomedicine; 2015; 10():5475-87. PubMed ID: 26346750
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Zhang L; Yao J; Zhou J; Wang T; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
[TBL] [Abstract][Full Text] [Related]
16. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation.
Zhang X; Lin CC; Chan WK; Liu KL; Yang ZJ; Zhang HQ
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672816
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: An in vivo and in vitro study.
Sun S; Shang E; Ju A; Li Y; Wu Q; Li Q; Yang Y; Guo Y; Yang D; Lv S
Fitoterapia; 2021 Nov; 155():105033. PubMed ID: 34517057
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
Jiang S; Gong X; Zhao X; Zu Y
Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
[TBL] [Abstract][Full Text] [Related]
19. A promising targeted gene delivery system: folate-modified dexamethasone-conjugated solid lipid nanoparticles.
Wang W; Zhou F; Ge L; Liu X; Kong F
Pharm Biol; 2014 Aug; 52(8):1039-44. PubMed ID: 24611745
[TBL] [Abstract][Full Text] [Related]
20. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
